SCHEMBL4986987

SCHEMBL4986987

COc1cc(=O)n(-c2ccccc2)cc1CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.53
SRC P12931 1/20 0.53
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 5/20 0.45
HSD17B10 Q99714 4/20 0.45
HPGD P15428 3/20 0.45
MAPT P10636 2/20 0.44
COMT P21964 1/20 0.42
CYP1A2 P05177 1/20 0.41
BLM P54132 1/20 0.41
PLA2G4A P47712 2/20 0.41
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.40
KDM4C Q9H3R0 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP19A1 P11511 1/20 0.39
NQO2 P16083 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14215926 0.78 ALDH1A1 (0.50) FGFR1SRCALDH1A1KDM4EHSD17B10
SCHEMBL14188927 0.78 ALDH1A1 (0.51) FGFR1SRCALDH1A1KDM4EHSD17B10
SCHEMBL4983932 0.75 FGFR1 (0.54) FGFR1SRCALDH1A1KDM4EHSD17B10
SCHEMBL4980883 0.74 MAPT (0.48) FGFR1SRCALDH1A1KDM4EHPGD
SCHEMBL8149820 0.72 PDE5A (0.46) FGFR1SRCALDH1A1KDM4EHSD17B10
SCHEMBL24391596 0.70 RXFP1 (0.47) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL7987204 0.70 FGFR1 (1.00) FGFR1SRCALDH1A1HPGDCYP1A2
SCHEMBL4983202 0.69 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL17509826 0.69 CYP19A1 (0.66) SRCALDH1A1KDM4EHSD17B10HPGD
SCHEMBL12494435 0.67 CYP1A2 (0.57) FGFR1SRCALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B FGFR1 737/4885SRC 2763/4885ALDH1A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.